TransCode Therapeutics Reports Phase 1a Results
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has recently completed its Phase 1a clinical trial for TTX-MC138, an innovative therapeutic designed to target microRNA-10b, key in various metastatic diseases. The company’s announcement marks a significant milestone, as they achieved the primary safety endpoint, paving the way for further evaluation.
Key Findings from the Trial
The trial was primarily focused on assessing safety, pharmacokinetics, and determining a recommended Phase 2 dose (RP2D). A total of sixteen patients participated, receiving treatments across four escalating dose levels, and importantly, no significant treatment-related safety events or dose-limiting toxicities were observed.
Among the participants, there was a median treatment duration of four months, with some patients remaining on the trial longer, ranging from two to twelve months. Remarkably, data from the trial revealed that approximately 44% of patients showed stable disease lasting more than four months, indicative of the therapy's potential effectiveness.
Clinical Insights and Physician Evaluations
Dr. William McKean, a study investigator from The START Center for Cancer Research, emphasized the promising clinical benefits observed in the treated patients. The data suggests a compelling link between TTX-MC138's mechanism of action and the observed effects. This promising start encourages the transition to further evaluate efficacy in a larger patient cohort.
Moreover, reports from the ongoing monitoring reveal positive pharmacodynamic effects, which align with those from earlier preclinical investigations. This shift points to TTX-MC138’s capacity to impact disease trajectories positively, offering hope for a new treatment paradigm for advanced malignancies.
Next Steps in Clinical Development
As analysis and data monitoring continue, TransCode intends to advance TTX-MC138 into a Phase 2a study. Daniel Vlock, MD, Consulting Clinician for TransCode, remarked on the significance of the observed safety profile and durability of anti-tumor effects, framing this as an impressive step forward in combating metastatic diseases.
About TTX-MC138
TTX-MC138 stands out as a first-in-class candidate, engineered to disrupt microRNA-10b activity, a crucial factor in the development and progression of many forms of metastatic cancer. Previous trials, including a Phase 0 clinical trial, demonstrated the investigational compound's effective delivery and pharmacodynamic activity, even at reduced dosage levels, indicating a wide therapeutic window and substantial potential.
About TransCode Therapeutics
Dedicated to revolutionizing cancer treatment, TransCode Therapeutics specializes in developing immuno-oncology therapies aimed at advanced malignancies. The organization’s primary therapeutic candidate emphasizes targeting metastatic tumors characterized by the overexpression of microRNA-10b, alongside a portfolio of additional innovative candidates designed to engage the immune system in combating cancer effectively.
Frequently Asked Questions
What is TTX-MC138?
TTX-MC138 is an investigational drug designed to inhibit microRNA-10b, crucial in the emergence and progression of metastatic cancers.
What were the safety results from the Phase 1a trial?
The Phase 1a trial achieved its primary safety endpoint, with no significant treatment-related safety events or dose-limiting toxicities reported among participants.
How many patients were involved in the trial?
A total of sixteen patients participated in the Phase 1a trial, treated across different dosing levels.
What are the next steps for TTX-MC138?
TransCode Therapeutics plans to advance TTX-MC138 into a Phase 2a clinical trial to further assess its efficacy.
How does TTX-MC138 work?
TTX-MC138 targets and inhibits microRNA-10b, which plays a crucial role in the development and spread of metastatic tumors, aiming to provide better therapeutic options.
